Fox Run Management L.L.C. Acquires 15,189 Shares of ADMA Biologics Inc $ADMA

Key Points

• Fox Run Management L.L.C. increased its holdings in ADMA Biologics Inc by 79.5% in the first quarter, resulting in a total investment valued at $681,000.
• Institutional investment in ADMA Biologics is significant, with hedge funds owning approximately 75.68% of the stock, indicating strong market confidence.
• ADMA Biologics reported a net margin of 44.06% for the latest quarter, with a revenue increase of 13.8% year-over-year, showcasing its financial growth.

Fox Run Management L.L.C. increased its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 79.5% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 34,306 shares of the biotechnology company's stock after acquiring an additional 15,189 shares during the period. Fox Run Management L.L.C.'s holdings in ADMA Biologics were worth $681,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ADMA. Invesco Ltd. boosted its holdings in shares of ADMA Biologics by 13.9% in the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock worth $255,279,000 after purchasing an additional 1,570,649 shares in the last quarter. Nuveen LLC bought a new stake in ADMA Biologics in the 1st quarter worth approximately $93,543,000. Dimensional Fund Advisors LP boosted its stake in ADMA Biologics by 16.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after buying an additional 643,661 shares in the last quarter. Oberweis Asset Management Inc. boosted its stake in ADMA Biologics by 15.0% in the fourth quarter. Oberweis Asset Management Inc. now owns 3,342,560 shares of the biotechnology company's stock worth $57,325,000 after buying an additional 435,480 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in ADMA Biologics by 7.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 3,048,946 shares of the biotechnology company's stock valued at $59,211,000 after acquiring an additional 207,097 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the transaction, the director directly owned 94,830 shares in the company, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of the business's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the transaction, the director owned 478,194 shares in the company, valued at $10,190,314.14. This represents a 2.05% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 455,621 shares of company stock valued at $9,461,633. 3.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ADMA has been the subject of a number of recent research reports. Raymond James Financial boosted their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $27.67.

ADMA Biologics Trading Up 2.3%

NASDAQ:ADMA traded up $0.3850 during mid-day trading on Friday, reaching $17.4850. 615,777 shares of the company's stock traded hands, compared to its average volume of 3,116,961. The company has a 50 day moving average price of $17.97 and a 200-day moving average price of $18.87. The firm has a market capitalization of $4.17 billion, a price-to-earnings ratio of 20.37 and a beta of 0.38. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same period last year, the company earned $0.13 EPS. The business's quarterly revenue was up 13.8% compared to the same quarter last year. On average, sell-side analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.